While data from the much-anticipated FLEX Phase III study showed that ImClone Systems Inc.'s Erbitux (cetuximab) prolonged life by about five weeks for patients with non-small-cell lung cancer (NSCLC), findings from another study of the drug in colorectal cancer showed that patients with the KRAS gene mutation were unlikely to benefit from Erbitux. (BioWorld Today) Read More
